A phase I study to evaluate the safety and pharmacokinetics of ONX 0801 in advanced solid tumours
| ISRCTN | ISRCTN79302332 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN79302332 |
| Secondary identifying numbers | 2009-001 |
- Submission date
- 12/06/2009
- Registration date
- 30/06/2009
- Last edited
- 12/12/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Lynne Bui
Scientific
Scientific
2100 Powell Street
Emeryville
94608
United States of America
Study information
| Study design | Phase I open-label dose-finding study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details provided in the interventions section to request a patient information sheet |
| Scientific title | A phase I, open-label, dose-finding study to evaluate the safety and pharmacokinetics of ONX 0801, a novel alpha-folate receptor-mediated thymidylate synthase inhibitor, in patients with advanced solid tumours |
| Study objectives | Is ONX 0801 tolerable and safe in cancer patients and can a dose be identified which inhibits tumour cell growth in future clinical studies? |
| Ethics approval(s) | Royal Marsden Hospital Ethics Committee and the Hammersmith Ethics Committee – submission pending, planned for June 2009 |
| Health condition(s) or problem(s) studied | Advanced solid tumours |
| Intervention | Cohorts of 3 to 6 patients will receive ONX 0801 at escalating doses until a maximum tolerated dose (MTD) is determined. Each patient will receive a 3-hour intravenous (IV) infusion of ONX 0801 weekly (i.e., on days 1, 8, and 15) of repeated 21-day treatment cycles. Contact details for patient information material: Udai Banerji, MD, MRCP, PhD Clinical Senior Lecturer Section of Medicine Institute of Cancer Research The Royal Marsden Hospital 15 Cotswold Road Sutton, UK SM2 5NG +44 (0) 20 8661 3993 |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase I |
| Drug / device / biological / vaccine name(s) | ONX 0801 |
| Primary outcome measure | 1. To determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of ONX 0801 based on dose limiting toxicities (DLTs) occurring within cycle 1 2. To characterise the safety profile of ONX 0801 |
| Secondary outcome measures | 1. Pharmacokinetics (PK) of ONX 0801: Blood samples will be collected according to the following schedule: 1.1. Cycle 1, Day 1: predose and 30 minutes and 1, 2, 3, 3.5, 4, 6, 8, 12, 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours following the start of the infusion 1.2. Cycle 1, Days 8 and 15: predose and 3 hours following the start of the infusion 1.3. Cycle 2, Days 1 and 8: predose and 3 hours following the start of the infusion 2. Pharmacodynamics of ONX 0801: 2.1. Blood samples will be collected according to the following schedule: predose and 4, 8, 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours following the start of infusion in Cycle 1, Day 1 and approximately every 6 - 9 weeks during the course of the study 2.2. Tissue samples may be collected predose and up to 72 hours following the start of the infusion in Cycle 1, Day 1 2.3. 18FLT-PET scans may be performed predose and between 16 to 48 hours following the start of the infusion in Cycle 1, Day 1 3. Identifying a biologically effective dose (BED) equal to or lower than the MTD and/or RP2D of ONX 0801 4. Assess the preliminary antitumour activity of ONX 0801 |
| Overall study start date | 30/09/2009 |
| Completion date | 30/03/2011 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 60 |
| Key inclusion criteria | 1. Histologically or cytologically proven solid tumours, including lymphomas. Patients must have disease which has failed standard therapy or for which no standard curative therapy exists. 2. Greater than or equal to 18 years of age, either sex 3. Eastern Cooperative Oncology Group performance status (ECOG PS) less than or equal to 2 4. Life expectancy greater than or equal to 12 weeks 5. Measurable (as defined by Response Evaluation Criteria in Solid Tumours [RECIST version 1.1]) or evaluable (based on radiological assessments or tumour markers) disease 6. Recovered (i.e., to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Version 3.0 Grade less than or equal to 1) from all toxicities associated with previous chemotherapy or radiotherapy (exception: patients may enter with continuing alopecia irrespective of CTCAE grade). The following intervals between starting last treatment and starting ONX 0801 must elapse: 6.1. Chemotherapy (see exception below): at least 4 weeks 6.2. Mitomycin C or a nitrosourea: at least 6 weeks 6.3. Targeted therapy: at least 2 weeks or 2 half-lives, whichever is longer 6.4. Biologics: at least 4 weeks 6.5. Radiotherapy: at least 4 weeks 7. Normal organ function 8. Normal electrocardiogram (ECG) 9. Archival tumour tissue available |
| Key exclusion criteria | 1. Pregnant women, women who are lactating, or women of childbearing potential who are not currently on effective means of birth control 2. History of QT/QTc prolongation, clinically significant ventricular tachycardia, ventricular fibrillation, heart block, myocardial infarction within 1 year, congestive heart failure New York Heart Association Class III or IV, unstable angina, angina within 6 months, or other evidence of clinically significant coronary artery disease 3. Active, ongoing infection, including viral hepatitis 4. Undergone major surgery within the last 4 weeks 5. Organ transplant recipients 6. New brain metastasis. Patients with treated (surgically excised or irradiated) and stable brain metastases are eligible as long as the treatment was at least 4 weeks prior to initiation of study drug and baseline brain computed tomography (CT) with contrast or magnetic resonance imaging (MRI) within 2 weeks of initiation of study drug is negative for new brain metastases. 7. Patients who have been on other experimental clinical trials of investigational agents within the last 28 days |
| Date of first enrolment | 30/09/2009 |
| Date of final enrolment | 30/03/2011 |
Locations
Countries of recruitment
- United Kingdom
- United States of America
Study participating centre
2100 Powell Street
Emeryville
94608
United States of America
94608
United States of America
Sponsor information
Onyx Pharmaceuticals (USA)
Industry
Industry
2100 Powell Street
Emeryville
94608
United States of America
| Website | http://www.onyx-pharm.com/wt/page/index |
|---|---|
"ROR" |
https://ror.org/03g03ge92 |
Funders
Funder type
Industry
Onyx Pharmaceuticals (USA)
Private sector organisation / For-profit companies (industry)
Private sector organisation / For-profit companies (industry)
- Location
- United States of America
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Editorial Notes
12/12/2017: No publications found in PubMed, verifying study status with principal investigator.
